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Abstract
Background: In order to induce a potent and cross-reactive neutralizing antibody (nAb), an effective envelope
immunogen is crucial for many viral vaccines, including the vaccine for the human immunodeficiency virus (HIV).
The Chinese equine infectious anemia virus (EIAV) attenuated vaccine has controlled the epidemic of this virus
after its vaccination in over 70 million equine animals during the last 3 decades in China. Data from our past
studies demonstrate that the Env protein of this vaccine plays a pivotal role in protecting horses from both
homologous and heterogeneous EIAV challenges. Therefore, the amino acid sequence information from the
Chinese EIAV attenuated vaccine, in comparison with the parental wild-type EIAV strains, was applied to modify the
corresponding region of the envelope glycoprotein of HIV-1 CN54. The direction of the mutations was made
towards the amino acids conserved in the two EIAV vaccine strains, distinguishing them from the two wild-type
strains. The purpose of the modification was to enhance the immunogenicity of the HIV Env.
Results: The induced nAb by the modified HIV Env neutralized HIV-1 B and B′/C viruses at the highest titer of
1:270. Further studies showed that a single amino acid change in the C1 region accounts for the substantial
enhancement in induction of anti-HIV-1 neutralizing antibodies.
Conclusions: This study shows that an HIV envelope modified by the information of another lentivirus vaccine
induces effective broadly neutralizing antibodies. A single amino acid mutation was found to increase the
immunogenicity of the HIV Env.
Background
Both EIAV and HIV are members of the Lentivirus
genus of the Retroviridae family [1,2]. Although the clin-
ical manifestations of infections by EIAV and HIV are
different, the underlying mechanisms of persistence and
pathogenesis are very similar [3,4]. These similarities are
based on the common genetic organization, the molecu-
lar mechanism of viral replication, and the conforma-
tional structures of the viral structural proteins [5-9].
Most chronically infected horses survive the subclinical
carrier phase after recurring cycles of fever, anemia,
weight loss, and thrombocytopenia [10,11]. Therefore,
EIAV has been used as a model to study HIV-1 persis-
tence, pathogenesis, and immune responses [12-17].
Despite many years of ongoing research, an effective
HIV vaccine has not yet been developed. The first suc-
cessful lentivirus vaccine was an EIAV vaccine, which
was made 30 years ago [18,19]. Therefore, the EIAV
vaccine can serve as a good model to identify the
mechanisms of immune responses against lentiviruses
and shed light on how to design an effective HIV vac-
cine. Studies on the animal models of EIAV, FIV, and
SIV showed that attenuated vaccines can be highly effec-
tive against infection by wild-type strains [18-22]. The
Chinese EIAV donkey-leukocyte attenuated vaccine
(DLV) was developed through long-term tissue culture
attenuation (123 passages) from a highly pathogenic
EIAV strain D510. The latter was obtained from in vivo
passages (17 and 117 passages in horses and donkeys
respectively) of a field EIAV isolates, LN40 strain. The
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about 80% of vaccinated horses resisting challenge by
homogeneous and heterogeneous virulent EIAV strains
[18,19].
The envelope protein of EIAV plays a pivotal role in
the receptor binding on target cells, the subsequent
entry into the cell, and the induction of humoral
immune responses [23-25]. Previous work with EIAV,
FIV as well as SIV has shown that there is a progressive
maturation of Env-specific antibody responses to various
attenuated lentiviral vaccines [15,26-28]. The mature
immune responses including high titer and high avidity
can be enhanced by a modified Env, leading to protec-
tive vaccine immunity [15,26-29]. Towards this objec-
tive, the current studies were conducted. We enhanced
the immunogenicity of the HIV Env by making certain
envelope mutations associated with the effective EIAV
vaccine.
Results
Vaccines Construction
From the sequence analysis of two Chinese vaccine-
derived wild-type EIAV strains (LN40 and D510) and
two vaccine virus strains (DLV and FDDV), 10 consen-
sus amino acid mutations were identified in the EIAV
Env region [2] (Figure 1a). We modified the HIV-1
gp145 DNA vaccine and recombinant vaccinia vaccine
by introducing all of the EIAV amino acid mutations
(Table 1 and Figure 1b). They were based on the struc-
tural information of the attenuated EIAV vaccine [5,6]
(Figure 1c). We used the gp145 derived from CN54
[Genbank: AX149771], which belongs to the most pre-
valent CRF BC_07 in China [30], as the template. Details
on these constructions are provided in the Methods.
Gp145-10 M enhanced the humoral immune responses
Env-specific binding antibody responses
BALB/c mice were immunized four times with the DNA
vaccine SV1.0, SV145, and SV145-10 M at intervals of
two weeks and were sacrificed at three weeks after the
last inoculation (Figure 2a). The sera of the SV145-
10 M group produced binding antibodies at a titer of
1:800. This amount of antibodies was 3.5 times higher
than that elicited by SV145 (P = 0.0020). The mock vec-
tor (SV1.0) control group only generated a background
of antibodies at <1:100 (Figure 2b).
Figure 1 Consensus mutations and schematic structures are similar between EIAV and HIV-1. a) Sequence analysis show 10 consensus
amino acid mutational sites that have been identified between two Chinese vaccine-derived wild-type EIAV strains and two vaccine virus strains
in the EIAV Env region ("–” means that this amino acid was deleted). b) Schematic illustration of gp145 mutants. The figure after the M
represents the region of mutations made in the CN54 gp145. c) Schematic figure of the EIAV D510 V3, V4 regions and the HIV-1 CN54 V1, V2
regions. The left figure shows the EIAV V3, V4 regions; the right figure shows the HIV-1 V1, V2 regions. N-Glycosylation sites are shown as
branched lines.
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Page 2 of 13Neutralizing antibody responses in BALB/c mice
Neutralizing antibodies were determined with HIV-1
primary isolates (B′/C clade isolates XJDC6371,
XJDC6431, XJDC0793, CBJB105, CBJB248 and B′ clade
isolate 020201300). The serum neutralization titer was
determined by assessing whether the sera could neutra-
lize 50% of the virus in triplicate. If the value of 1/50%
neutralization titer is 6, it means the sera neutralized
more than 50% of the virus at the dilution of 1:6. Sera
from all gp145 immunized mice failed to neutralize any
of the B′/C clade isolates even at the lowest titer of 1:6.
Notably, the sera of the gp145-10 M immunized mice
neutralized all five of the B′/C clade primary viruses and
virus 020201300. Moreover, all mice neutralizing anti-
body titers from the gp145-10 M group were higher
than 1:12 and neutralized B′/C clade viruses XJDC6431,
XJDC0793, CBJB105, CBJB248 higher than 1:24
(Table 2).
Neutralizing antibody responses in guinea pigs
Neutralizing antibodies at a titer 1:10 in guinea pigs
model were tested at four and six weeks after the last
inoculation (Figure 3a). At least three of four sera from
gp145-10M-immunized guinea pigs neutralized all of
the B′/C clade and B′ clade viruses at six weeks (Figure
3b), and similar results were found at four weeks (data
not shown). Notably, the neutralization frequency in
gp145-10M-immunized animals was 2.5 fold higher than
that of gp145-immunized animals at the titer ≥1:10
(Figure 3b). Moreover, at least two of four sera collected
Table 1 List of the primers used in PCR for modification
Name Primer sequence (5’-3’)
CN54145F GCTCTAGAGATATCGACACCATGGACAGGGCCAAGCTGCTGCTG
CN54145R GTGAACAGGGTGAGGCAGGGCTACTGAGGATCCGTCGACCG
145M1u ACCACCGAGTTCTGCGCCAGCGACG
145M1d CGCAGAACTCGGTGGTGGTGGCGCCCTTCCACACGG
145M2u AACCAGGACACCTACCACGAGACC
145M2d CTCCTCGTGGTAGGTGTCCTGGTTGCTGCTCACGTTCCT
145M3u ACCGTGGTGGAGGACAGGAAGCAGAC
145M3d TTCCTGTCCTCCACCACGGTGGTGGCGTTG
145M4u CTACGAGAAGAACAGCCAGGAGTACTACAGGCTGATC
145M4d CCTGGCTGTTCTTCTCGTAGTTCTTCTTGGT
145M5u ATCTTCAACCGCACCCAGCCCTGCTACAACGTGAGCACCG
145M5d GTTGTAGCAGGGCTGGGTGCGGTTGAAGATCTTGTC
All mutations in primers are marked with bold text.
Figure 2 Specific binding antibody titer. a) Vaccine inoculation schedule of mice. All groups were inoculated with DNA vaccine at Weeks 0, 2,
4 and 6 and then sacrificed at Week 9 to assess cellular and humoral immune responses. b, c & d) The specific binding antibody titer induced
by DNA vaccines. Antibody reactivity was then determined by measuring the optical density (OD) at 492 nm, and endpoint titers were
determined by the last dilution whose OD was >two-times than that at the average corresponding dilution of mice sera immunized with SV1.0.
The Y value is the log value of the endpoint titers. The significance of differences among the different groups was calculated using a statistical
method of one-way analysis of variance (GraphPad prism4.0); * p < 0.05, ** p < 0.01. We obtained data from three experiments using fresh sera.
Liu et al. Retrovirology 2010, 7:71
http://www.retrovirology.com/content/7/1/71
Page 3 of 13from the gp145-10M-immunized guinea pigs showed
80% neutralization at the titer of ≥1:10 (data not
shown). In contrast, only one of four sera collected from
the gp145-immunized animals had 50% neutralization at
the titer of ≥1:10; and only three possible events were
found in the gp145-immunized group. Lastly, but most
importantly, antibodies induced by gp145-10 M neutra-
lized all HIV-1 isolates and pseudotyped viruses at the
highest endpoint titers of 1:270 (Figure 4a,b). The mean
neutralization titers from mock-, gp145- and gp145-
10M-immunized groups against all viruses were 0, 1:16
and 1:71, respectively (Figure 4a). Two sera of the
gp145-10M-immunized guinea pigs neutralized all
viruses at titers of 1:98 and 1:158.
Linear antibody epitope mapping
The results of the PLL-ELISA demonstrated that differ-
ent antibodies to specific linear epitopes were induced
among gp145- and gp145-10M-immunized mice (Figure
5). In the C1 region, both gp145 and gp145-10 M
induced antibodies to peptide 4840, and the latter
enhanced the response. The gp145-10M-immunized ani-
mals failed to generate antibodies to peptides 4838, 4859
and 4860, but they induced strong antibody responses to
Table 2 Neutralization titer against HIV-1 clinical isolates in BALB/c mice
Vaccine groups Neutralization titer against HIV-1 isolates
XJDC6371 XJDC6431 XJDC0793 CBJB105 CBJB248 020101300
SV145 < 6 < 6 < 6 < 6 < 6 > 12
SV145-10M > 12 > 24 > 24 > 24 > 24 > 12
SV145M1&2 < 6 > 24 > 24 > 24 > 24 > 24
SV145M1 < 6 > 24 > 24 > 24 > 24 > 24
SV145M2 < 6 > 12 > 12 > 12 > 12 > 12
SV145M3 < 6 < 6 < 6 < 6 > 12 > 12
SV145M4 < 6 < 6 < 6 < 6 > 12 > 12
SV145M5 < 6 < 6 < 6 < 6 < 6 < 6
The neutralization was conducted by using a panel of clinical isolates in PBMCs with 50% inhibitory dose. Gp145-10 M, gp145M1&2, gp145M1 and 145M2 groups
could neutralize HIV-1 isolates at the highest titer of 1:24, other than XJDC6371. The single N-glycosylation site deletion in the V1 loop designated as gp145M2
could induce broader neutralizing antibodies against five clinical isolates at a titer of 1:12.
Figure 3 Inhibition of HIV by sera of immunized guinea pigs at the titer of 1:10. a) Vaccine inoculation schedule of guinea pigs. All groups
were inoculated with DNA vaccine at weeks 0, 2, 4 and then boosted with rTV at week 10. Sera after last immunization were collected at week
14 and 16. b) Comparative inhibition of HIV-1 infection by sera collected at week 16 from mock-, gp145- and gp145-10M-immunized guinea
pigs. The neutralizing experiment was conducted by using a panel of clinical HIV-1 isolates from PBMCs in TZM-bl cells. The dotted line in the
figure indicates the 50% inhibition rate.
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Page 4 of 13peptide 4876 in the V5 loop and higher antibody titers
to peptides 4886 and 4887 in the HR region.
Env-specific T cell immune responses
HIV-1cn54 Env-specific T cell responses were also mea-
sured by the IFN-g-based ELISPOT assay after stimula-
tion of splenocytes with SHIVchn19 peptides from the
ENV1 and ENV2 pools. The ENV1 pool is made up of
the first 43 peptides (4830-4871), and the others com-
pose the ENV2 pool (4872-4913). The Env peptides of
SHIVchn19 are HIV-1 CN54 Env peptides. The data
showed no obvious difference between the gp145- and
gp145-10M-immunized mice (Figure 6a-d).
Gp145M1&2 enhanced immune responses Humoral
immune responses
Further studies were conducted in mice immunized with
gp145M1&2 (composed of mutations of both M1 and
M2), gp145M3, gp145M4, and gp145M5 (Figure 1b).
Notably, gp145M1&2 (similarly to gp145-10M) induced
higher specific binding antibodies than gp145 (p =
0.041). No significant specific binding antibody
differences were found in any other group (Figure 2c).
Moreover, the sera from the gp145M1&2-immunized
animals neutralized almost all of the B′/C isolates and B′
viruses at a titer greater than 1:24 (Table 2). The sera of
the gp145M3- and gp145M4-immunized groups neutra-
lized HIV-1 isolates CBJB248 and 020101300 with an
endpoint titer of 1:12 (Table 2). Overall, gp145M1&2
induced similar potent humoral immunity as gp145-10
M did.
Env-specific T cell immune responses
The specific cellular responses measured by the IFN-g
ELISPOT assay gave additional results in mice. The
gp145M1&2 immunization induced vigorous IFN-g
responses (1116 ± 165 SFC/10
6 splenocytes, N = 5),
which were significantly higher than those elicited in the
gp145 group (627 ± 118 SFC/10
6 splenocytes, N = 5) (p
= 0.043). A two-fold enhancement of the immune
response was achieved by the modification (Figure 6e,
h). Although the mutations of gp145M1&2 localized at
those epitopes covered by the ENV1 peptide pool, both
the ENV1 and the ENV2 peptide pools stimulated
Figure 4 Neutralizing antibody titers against HIV-1 of immunized guinea pigs’ sera. End-point neutralizing antibody titers of HIV-1 by sera
from mock-, gp145- and gp145-10M-immunized guinea pigs. Sera were collected at six weeks after the last immunization for testing. The
neutralizing experiment was conducted by using a panel of clinical isolates in PBMC cells (a) and a panel of tier 2-3 peudeovirus in TZM-b1 cells
(b). The 50% inhibitory dose (ID50) was defined as the plasma dilution.
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group than in the gp145 and gp145-10M-immunized
groups (Figure 6f, g).
Gp145M1 elicits the best immunity Humoral immune
responses
Two new mutants, SV145M1 and SV145M2, were
designed to evaluate the enhanced immunogenicity
induced by gp145M1&2. (Table 1) The mean specific
binding antibody titers were 1:1, 1:666, 1:2900, 1:2800
and 1:279 following immunization with SV1.0, SV145,
SV145M1&2, SV145M1 and SV145M2, respectively
(Figure 2d). Inoculation with gp145M1&2 and gp145M1
stimulated higher binding antibodies than any other
modified gp145. Although the sera from the mice,
immunized with gp145M2, neutralized almost all HIV
isolates (whether B′/C clade or B clade) at a titer greater
than 1:12, the gp145M1-immunized animal sera neutra-
lized viruses at a titer higher than 1:24 (Table 2).
Env-specific T cell immune responses
The results also showed that Env-specific T cellular
immunity was enhanced to a similar level by both the
SV145M1&2 and SV145M1 DNA vaccines to the
peptides pool of either ENV1 or ENV2 (Figure 6i, k,
l &6m). Therefore, gp145M1 appears to be the most
important mutation for enhancing the anti-HIV immune
response.
Discussion
The HIV-1 envelope glycoprotein is the primary target
for neutralization, and great efforts have been made to
enhance the immunogenicity of Env in AIDS vaccine
design. Although the primary goal for studies of Env
modification is to elicit cross-reactive neutralizing anti-
bodies responses [27,31-38], specific binding antibodies
have also been shown to contribute to vaccine-induced
protection [28]. Moreover, one study in rhesus monkeys
demonstrated that specific T cellular responses elicited
by HIV Env contributed to vaccine-induced protection
from challenge viruses carrying a heterologous envelope
[39]. Similar T cell results were found in the vaccination
with the EIAV vaccine EIAVD9 [40]. Another study
showed that specific modifications in HIV Env also
enhanced the ability to induce broader CD8+ T cell
activities [41].
With this information in mind, we performed com-
parative studies of the structural and functional changes
Figure 5 Linear antibody epitope mapping. PLL-ELISA was used to detect the responses of the antibody against each linear peptide. The
concentration of each peptide of HIVCN54gp145 was 10 μg/ml. In these epitopes, seven were defined as positive (> two-fold background).
Epitopes p4838, p4859 and p4860 were only identified in the SV145 group. P4876 was only defined in the SV145-10 M group. The grey line in
the figure indicates the threshold value (0.22), which is two times than the average OD values (0.11) from mock controls. Five mutation regions
were labeled.
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Page 6 of 13Figure 6 Specific IFN-gamma secretion detected by ELISPOT. The T cell immunity was quantified with an IFN-g-based ELISPOT assay with
SHIVchn19 (20-mer) peptides ENV1 (4830-4871) or ENV2 pools (4872-4913). a, e & i) Elispot results in different immunized groups stimulated with
stimuli as indicated on the left. b, f & k) Number of SFC in one million splenocytes stimulated by the ENV1 pool. c, g & l) Number of SFC in one
million splenocytes stimulated by the ENV2 pool. d, h & m) Env-specific T cell responses against these two peptide pools were compiled
together as the total T cell responses for each mouse and were graphed into groups. The mock group generated <50 SFCs/10
6 splenocytes. The
significance of differences among the different groups was calculated using a statistical method of one-way analysis of variance (GraphPad
prism4.0); SFC, spot forming cell; * p < 0.05, ** p < 0.01. The error bars indicate SEM (the standard error of the mean).
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The critical mutations found in EIAV were introduced
into HIV Env based on their conserved secondary struc-
ture and glycosylation properties [5,6] (Figure 1). The
purpose of the modification was to increase the
immunogenicity of HIV Env.
The modified immunogen gp145-10 M (containing all
10 mutations) induced broad and high neutralizing anti-
body titers both in mice and guinea pigs. All primary
HIV-1 isolates could be neutralized by the gp145-10M-
i m m u n i z e ds e r a( T a b l e2 ,F i g u r e3& 4 ) .A d d i t i o n a ls t u -
dies showed similar results following immunization with
gp145M1&2 and gp145M1 (Table 2). Both neutralizing
antibodies and specific binding antibodies were greatly
enhanced in quality as well as in quantity (Figure 2 &
Table 2).
The PLL-ELISA data showed that antibodies to speci-
fic linear epitopes were different between the wild-type
gp145- and gp145-10M-immunized groups. However,
these different epitopes did not match the mutation
sites (Figure 5). We hypothesized that there were con-
formational changes induced by the modification
because the locations of the epitopes were interspersed
in the whole envelope. In fact, studies of the secondary
structure of these antigens demonstrated one major
change in the C1 region caused by the M1 mutation, in
which one b-sheet was changed to an a-helix structure
compared to gp145 (Figure 7a, b). Furthermore, a 14-
amino acid segment within the C1 region that was ori-
ginally hydrophobic is now amphipathic (Figure 7c, d).
These changes may cause the exposure of some conser-
vative epitopes. In this regard, our data suggest that the
mutation in the C1 region causes a polarity change of
the 14 amino acids and that it induces the exposure of
conserved epitopes to stimulate stronger and broader
neutralizing antibodies. Other mutations elicit fewer
changes in the secondary structure but cause no polarity
changes (data not shown).
In addition to the potent neutralizing antibodies and
specific binding antibodies observed in the group
Figure 7 The secondary structure prediction and hydrophilicity changes of antigens. AnthePro5.0 software was applied to predict the
secondary structure and hydrophilicity changes of gp145 and gp145M1. The red rectangle labels the changed profiles. a & b) The secondary
structure predictions of gp145 and gp145M1. a-helix in blue bar; b-sheet in orange bar; b-turn in green bar; others in black bar. c & d) The
difference in hydrophilicity between gp145 and gp145M1. The Y-axis shows the value of predicted hydrophilicity.
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Page 8 of 13immunized with gp145M1 and gp145M1&2, high levels
of secretion of IFN-g specific to the ENV1 and ENV2
peptides pools were induced (Figure 6). Because the
mutations were modified at the C1 and the V1 regions,
the enhancement of specific T cell response to the
ENV2 peptides pool was noteworthy. Future studies will
focus on the influence of different mutations on the
process of antigen presentation [42-45]. Importantly,
this study showed that one amino acid change in the C1
region induced potent anti-HIV-1 responses involving
specific binding antibodies, neutralizing antibodies, and
cellular immunity.
Methods
DNA vaccine construction
H I V - 1C N 5 4i s o l a t e di nt h ee a r l yp r e v a l e n c eo fH I V - 1
in China may be considered as an ancestor strain,
though the sequence data to establish this concept
remains unavailable. The gp145 gene was acquired using
PCR amplification from the codon-optimized gp160
gene of CN54. Then, the SV145 plasmid containing
gp145 gene was constructed using vector SV1.0 (pDRVI
SV1.0). The SV1.0 vector carries a kanamycin resistance
gene and a 72-bp element of the SV40 enhancer. Con-
sensus amino acid mutations were identified in the
EIAV Env from the sequence analysis of two wild-type
EIAV strains, LN40 and D510, and two vaccine virus
strains, DLV and FDDV (vaccine developed through 12
passages in fetal donkey dermal cells from DLV). The
amino acid modification sites of gp145 were determined
by aligning the envelope of EIAV and HIV-1 CN54 with
the sequence of the amino acid, the structure of the
variable loop and conserved regions, the location of con-
served glycosylation sites and the intra-chain disulfide
bond sites [1,5,6,46-48] (Figure 1c). Mutants of gp145
were generated by site-directed mutagenesis with two
pairs of the primers (Table 1). The resulting vaccines
were designated as SV145M1, SV145M2, SV145M3,
SV145M4, SV145M5, SV145M1&2 and SV145-10 M,
respectively. SV145M1 contains the first mutation L42E;
SV145M2 contains mutations S128-(deleted) and
N129Q; SV145M3 contains one mutation R155E;
SV145M4 contains three mutations S179E, E180K and
S183Q; SV145M5 also contains three mutations G230R,
G232Q and H235Y. SV145M1&2 was composed of
mutations of M1 and M2. SV145-10 M contains all the
ten mutations, respectively (Figure 1b). All constructs
were confirmed by double-strand gene sequencing.
Recombinant Tiantan vaccinia vaccine (rTV) construction
Gp145 and gp145-10 M genes were cloned into the
pSC65 shuttle plasmid (with a Lac Z gene as a screening
marker), which was designed to recombine specifically
with the TK gene of the Tiantan vaccinia virus.
Subconfluent monolayers of 143B cells were grown in
Eagle′s media containing 10% fetus bovine serum (FBS)
and 1% Penicillin-Streptomycin-L-glutamine. The cells
were washed with Eagle’s media in the absence of FBS.
Five million pfu vaccinia viruses were inoculated 143B
cells for one hour at 37°C and 5.0% CO2. Thereafter, the
vaccinia-infected cells were further transfected with
recombinant shuttle plasmids with Lipofectamine 2000
(CAT#11668-019, Invitrogen). After a 48-hour incuba-
tion, the transfection medium was removed and all wells
were covered with 2% melted low-melting temperature
(LMP) agarose mixed with an equal volume of 2×
Eagle’s media containing 100 μg/ml x-gal. The blue Lac
Z-positive colonies were picked up and further purified
in 143B cells under the pressure of a selection media
(Eagle’s media containing 50 μg/ml BrdU). The purified
recombinant Tiantan vaccinia viruses were confirmed by
PCR amplification of the inserted gp145, gp145-10 M.
The generated vaccines were designated as rTV145 and
rTV145-10 M. All rTVs were expanded in primary
chicken embryo cells.
Immunization of BALB/c mice
Female BALB/c mice (six weeks old, 18-22 g) were pur-
chased from the Institute of Laboratory Animal Science,
Chinese Academy of Medical Sciences & Peking Union
Medical College. All animals experiments were reviewed
and approved by the Institutional Animal Care and Use
Committee (IACUC) at the China CDC animal facility
and were performed in accordance with relevant guide-
lines and regulations. A sample of 100 μg of purified
plasmid DNA was suspended in 100 μlo fP B Sa n d
inoculated intramuscularly into the tibialis anterior four
times at intervals of two weeks. The mice were sacri-
ficed at three weeks after the last inoculation. Spleno-
cytes were freshly collected for Elispot assays, and sera
were collected and stored at 4°C and -80°C for future
quantification of antibodies.
Immunization of guinea pigs
Female Huntley guinea pigs (six weeks old) were pur-
chased from the Center of Laboratory Animal Science,
National Institute for the Control of Pharmaceutical and
Biological Products. All animal experiments were
reviewed and approved by the Institutional Animal Care
and Use Committee (IACUC) at the China CDC animal
facility and were performed in accordance with relevant
guidelines and regulations. A sample of 500 μgo fp u r i -
fied plasmid DNA of SV1.0, SV145 and SV145-10 M
was suspended in 500 μl of PBS. A group of four guinea
pigs were intramuscularly injected three times at Weeks
0, 2 and 4. Thereafter, guinea pigs in each group were
boosted with 1 × 10
7 pfu recombinant Tiantan Vacci-
nia-vectored vaccines at six weeks after the last DNA
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after the last inoculation and stored at 4°C and -80°C
for future quantification of antibodies.
HIV-1 CN54 envelope-specific binding antibody assay
Purified HIV-1cn54 gp120 (more than 85% purity) was
resolved in sodium bicarbonate buffer (pH 9.6) at a final
concentration of 4 μg/ml, and 100 μl was added to each
well of 96-well flat-bottom plates (Costar, NY). Plates
were coated at 4°C overnight, then washed twice with
PBS and blocked at 37°C for one hour with blocking
solution (PBS containing 5% skimmed dry milk). Mice
sera were serially two-fold diluted in blocking solution,
and 100 μl of diluted sera was added to each well. After
incubating the plates at 37°C for one hour, the plates
were then washed five times with PBS-T (PBS contain-
ing 0.05% Tween20), and 100 µl/well of peroxidase-con-
jugated anti-mouse immunoglobulin G (diluted 1:2000
in block solution) was added and incubated for 30 min-
utes at 37°C. The wells were washed again, and 100 μl
of OPD substrate (Cat# P9187, Sigma Aldrich) was
added and incubated for approximately 10 minutes at
room temperature. Color development was terminated
by the addition of 50 μl/well 2 N sulfuric acid. Antibody
reactivity was then determined by measuring the optical
density (OD) at 492 nm with an automated plate reader
(Multiscan Ascent, Thermo Corporation, Finland). End-
point titers were determined by the last dilution whose
OD was >two-fold that of the corresponding dilution of
the control sera.
Linear antibody epitope mapping
A method of PLL-ELISA was employed in this study
[28,49]. PLL (poly-L-leucine, 30-70 kDa, Sigma Aldrich)
was dissolved at the concentration of 40 μg/ml in the
sodium bicarbonate buffer, and 50 μl/well of PLL solu-
tion was added to a 96-well ELISA plate and incubated
at room temperature for one hour. The plate was
washed once with PBS, incubated with 50 μl per well of
1% (v/v) glutaraldehyde (Sigma Aldrich) in PBS at room
temperature for 15 minutes and washed twice with PBS.
Then, 50 μl/well of each peptide of SHIVchn19 (kindly
provided by the NIH Research and Reference Reagent
Program, NIAIDS, NIH, Cat# 4974: The Env of
SHIVchn19 is CN54 Env) in PBS was added at the con-
centration 10 μg/ml. The plates were incubated over-
n i g h ta t4 ° Ca n dt h e nw a s h e dt w i c ew i t hP B S .R e a c t i v e
aldehyde sites were blocked by the addition of 1 M gly-
cine, at 200 μl/well, for one hour at room temperature.
The plates were washed twice again with PBS and
blocked with 1 M glycine, at 100 μl/well, for one hour
at room temperature, and then they were incubated
with 100 μl/well of 0.5% skimmed dry milk:0.5% gelatin
(dissolved in PBS) for one hour. Mouse sera were
diluted at the ratio of 1:100 in PBS containing 5%
skimmed dry milk, and 50 μl/well of diluted sera was
added into the plates in duplicate and incubated at 37°C
for one hour. The plates were then washed four times
with PBS-T, incubated with 50 μl/well of diluted HRP-
linked second antibody (1:2000 diluted in PBS contain-
ing 2% skimmed dry milk, CAT# ZB-2305, Beijing
Zhongshan Biotech) at 37°C for one hour, washed five
times again with PBS-T and finally incubated with
50 μl/well of OPD substrate at room temperature in a
dark place for about 10 minutes. The reaction was ter-
minated with 50 μl/well 2 N sulfuric acid, and the OD
value for each well was read with an automated plate
reader at 492 nm. OD values of experimental settings
were displayed after subtraction of the background (that
is the OD value generated with sera from mock vector
control groups against the corresponding peptide), and
>two-fold average OD values of background were con-
sidered as positive.
HIV virus preparation and titration
HIV-1 primary viruses were isolated from patients’ per-
ipheral blood mononuclear cells (PBMCs) by Ficoll-
Paque gradient centrifugation (Amersham biosciences)
and co-cultured with phytohemagglutinin- (PHA)-stimu-
lated PBMCs from two HIV-1-seronegative human
donors. The cells were maintained in RPMI 1640 med-
ium (Gibco) containing 20 U/ml of recombinant inter-
leukin-2 (IL-2; National Institutes of Health; Bethesda,
Maryland, USA), 1% penicillin and streptomycin (P/S), 2
mM glutamine and 10% FBS. Five clade B′/C (CRF07)
HIV-1 (XJDC6371, XJDC6431, XJDC0793, CBJB105,
CBJB248) and four clade B′ HIV-1 (020100374,
020100259, 020100311, 020100691) clinical isolates were
used for this study [50]. Two clade B HIV-1 isolates
(SVPB16, SVPB17), two clade C HIV-1 isolates (SVPC5,
SVPC12) and three B′/C HIV-1 (CH91, CH110, CH119)
tier 2 pseudotyped viruses were used in neutralizing
antibody assay. There is no env sequence of these
viruses matched mutations.
The 50% tissue culture infectious dose (TCID50) of a
single thawed aliquot of each batch of virus was deter-
mined in TZM-BL cells. For TCID50 measurements,
serial five-fold dilutions of viruses were made in quadru-
plicate wells in 96-well culture plates in a total volume
of 100 μl of growth medium for a total of 11 dilution
steps. Freshly trypsinized cells (10,000 cells in 100 μlo f
growth medium containing 75 μg/ml DEAE-dextran)
were added to each well, and the plates were incubated
at 37°C in a humidified environment with 5% CO2.
After a 48-hour incubation, 100 μl of culture medium
was removed from each well and 100 μlo fB r i g h t - G l o
reagent (Luciferase Assay system, Promega) was added
t ot h ec e l l s .A f t e rat w o - m i n u t ei n c u b a t i o na tr o o m
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Page 10 of 13temperature to allow cell lysis, 150 μl of cell lysate was
transferred to 96-well black solid plates (Corning-
Costar) for measurements. The plates were read imme-
diately with a 1420 Multilabel Counter (PerkinElmer).
Wells producing relative luminescence units (RLU)
>three-fold background were scored as positive. Indina-
vir was added to the medium at a final concentration of
1 μM to prevent progeny virion production.
Neutralizing antibody assay
All mice and guinea pigs sera were heat-inactivated at
56°C for one hour prior to assaying. Volumes of 25 μl
of sera from different immunized mice groups were
diluted in 125 μl of DEAE-GM solution containing 10%
heat-inactivated FBS, 50 μg/ml gentamicin and 1 μM
indinavir to a 1:6 dilution. The diluted sera were further
two-fold diluted as 1:12 and 1:24 in 96-well plates. Gui-
nea pigs’ sera were three-fold diluted from titer 1:10 to
1:270. Thereafter, each well received 50 μl of cell-free
virus (200 TCID50). After one hour of incubation,
10,000 TZM-bl cells were added to each well. Plates
were incubated for 48 hours. Then, 100 μlo fm e d i a
removed, and Bright-Glo substrate was added to each
well. Percentages of RLU reduction were calculated as
(1- (Average RLU of duplicates with sample sera -
control wells)/(Average RLU from mock control sera -
control wells)) X100%. Neutralizing antibody titers were
expressed as the reciprocal of the serum dilution
required to reduce RLU by 50%.
IFN-g ELISPOT assay
HIV-1-specific T cell responses were measured using
the IFN-g ELISPOT assay kit (BD Biosciences, United
States). Plates were coated with purified anti-mouse
IFN-g at a concentration of 5 μg/ml, incubated at 4°C
overnight, then washed once with RPMI1640 containing
10% FBS and 1% Penicillin-Streptomycin-L-glutamine
and finally blocked for two hours at room temperature.
Mouse splenocytes (2 × 10
5) were added to wells in
duplicates. Cells were stimulated with the HIV-1 CN54
ENV1 or ENV2 peptide pools at 4 μg/ml each peptide.
The [SHIVchn19 (20-mer) peptides] ENV1 pool is made
up of the first 43 peptides (4830-4871), and others com-
pose the ENV2 pool (4872-4913). The positive control
was stimulated with PMA at 50 ng/ml and ionomycin at
1 μg/ml, and the negative control was stimulated with
medium only. The splenocytes were incubated at 37°C
and 5.0% CO2 for 24 hours and then lysed with sterile
water. Plates were washed three times with PBS-T prior
to one-hour incubation with biotinylated anti-mouse
IFN-g antibody, followed by the addition of streptavidin-
HRP for one hour at 37°C. Plates were washed again
and developed with 100 μl of AEC substrate solution for
10~30 minutes. The reaction was stopped by washing
with distilled water. IFN-g s p o t sw e r ea n a l y z e db ya n
automated ELISPOT plate reader (ImmunoSpot, C.T.L).
Spot-forming cells (SFCs) were defined as the average
number of spots in duplicate wells per 10
6 PBMCs.
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